Anti-p27 KIP 1 Rabbit pAb
WB analysis of p27 KIP 1.Sample: Protein treated by RIPA Lysis Buffer .Blocking buffer: 3% Nonfat dry milk in TBST, RT, 1h.Primary antibody: 1: 1000, 4℃ overnight.Secondary antibody: HRP conjugated Goat Anti-Rabbit lgG , 1: 5000, RT, 1h.
| Catalog Number: | ABS112176 |
| Conjugate: | unconjugated |
| Size: | 100 μL |
| Concentration: | 1mg/ml |
| Host: | Rabbit |
| Isotype: | IgG |
| Immunogen: | KLH conjugated Synthetic peptide corresponding to Mouse p27 KIP 1 |
| Reactivity: | Species, Human, Mouse, Rat |
| Applications: | Applications Dilution<br/>WB 1: 500-1: 1000 |
| Purification: | Affinity purification |
| Form: | Liquid |
| Synonyms: | CDKN1B, CDKN4, KIP1, MEN1B, MEN4, P27KIP1, cyclin-dependent kinase inhibitor 1B, cyclin dependent kinase inhibitor 1B,p27Kip1, Cdki1b, p27, Cyclin-dependent kinase inhibitor p27, P27-like cyclin-dependent kinase inhibitor |
CDKN1B, also named as P27 or KIP1, is a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. P27 binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controlling cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Downregulation of P27 has been implicated in the progression of several malignancies, including lung cancer, hepatocellular carcinoma, salivary cancer, oral squamous cell carcinomas, and gastric cancer.
Applications
Applications Dilution<br/>WB 1: 500-1: 1000
Immunogen
KLH conjugated Synthetic peptide corresponding to Mouse p27 KIP 1
